ODT’s Most-Read Stories This Week—Sept. 2

New funding and new product news drove the bulk of ODT website traffic this past week. 

Topping pageviews was word of Vertos Medical Inc.’s $26 million in Series C equity funding that will help the company expand patient access to the mild Procedure and support R&D efforts to advance care for patients with chronic low back pain.

Orthofix followed closely behind by announcing the full commercial launch and the first completed U.S. cases with its 7D FLASH Navigation Percutaneous Module 2.0. The product offers new planning features and more functionality for the 7D FLASH navigation system, which the company said can allow it to better serve the minimally invasive surgery spine market.

Medtronic enticed cybervisitors to the ODT site with news of CE mark approval for its Inceptive closed-loop, rechargeable spinal cord stimulator (SCS), the first of its SCS devices to offer a closed-loop feature that senses biological signals and adjusts stimulation moment to moment, as needed. Nalu Medical, meanwhile, amassed pageviews with an update on its COMFORT-2 peripheral nerve stimulation randomized controlled study, which aims to enroll the largest cohort of randomized controlled trial subjects comparing the responder rate of PNS combined with conventional medical management versus the responder rate of conventional medical management alone.

Also driving considerable site traffic this past week was an online exclusive report about the first innovation in ACL tear treatment in three decades. 

1. Vertos Medical Secures $26 Million in Series C Funding

2. Orthofix Fully Launches 7D FLASH Navigation System Percutaneous Module 2.0

3. Medtronic Earns EU Nod for Inceptiv Spinal Cord Stimulator

4. Nalu Medical Begins Enrollment in Peripheral Nerve Stimulation Trial

5. Revolutionizing ACL Restoration